View Exam | PowerPak

1. Overactive bladder (OAB) is linked to which of the following:

A. Structural changes in the urinary tract system B. Altered neurotransmitter function C. Caffeine use D. All of the above are possible causes of OAB symptoms

2. Treatment failure for OAB may be attributed to which one of the following:

A. Lack of efficacy for drug therapies B. The cost of OAB medications C. Lack of aggressive dosing D. Lack of time during office visits for thorough assessment

3. Which of the following is TRUE regarding OAB:

A. A disorder with an objective set of diagnostic criteria B. Easy to manage with use of evidence-based treatment algorithms C. Not influenced by other medical conditions; frequently a lone disorder D. A syndrome

4. Which of the following is a medication known to contribute to OAB:

A. Acetaminophen B. Rivaroxaban C. Diltiazem D. Guaifenesin

5. Which of the following is a preferable first-line or second-line treatment choice for OAB per the American Urological Association (AUA) guidelines:

A. Onabotulinumtoxin A B. Intradetrusor capsaicin injection C. Long-acting (LA) or extended-release (ER) oxybutynin D. Short-acting tolterodine

6. The medications that are used to treat OAB are

A. Never used for overflow incontinence B. Used the first time a patient notices a symptom of OAB, to prevent decline C. Only used to treat OAB symptoms in older adults D. To be used along with behavioral therapies

7. Mirabegron has which of the following side effects associated with its use:

A. Cardiac palpitations B. High post-void residual urine C. Dry mouth D. Low blood pressure

8. The bladder-specific alpha-adrenergic receptor antagonists target which one of the following:

A. The bladder detrusor muscle B. The limbic system C. The external urethral sphincter D. The internal bladder vesical sphincter

9. Which one of the following is a behavioral therapy for OAB:

A. Consuming more ice cream weekly B. Limiting the intake of caffeine C. Increasing expectations of treatment success with oral medications D. Ensuring that the patient uses OAB medications

10. Which of the following antimuscarinic medications is least likely to cross the blood-brain barrier:

A. Darifenacin B. Trospium C. Solifenacin D. Oxybutynin

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Overactive bladder (OAB) is linked to which of the following:

2. Treatment failure for OAB may be attributed to which one of the following:

3. Which of the following is TRUE regarding OAB:

4. Which of the following is a medication known to contribute to OAB:

5. Which of the following is a preferable first-line or second-line treatment choice for OAB per the American Urological Association (AUA) guidelines:

6. The medications that are used to treat OAB are

7. Mirabegron has which of the following side effects associated with its use:

8. The bladder-specific alpha-adrenergic receptor antagonists target which one of the following:

9. Which one of the following is a behavioral therapy for OAB:

10. Which of the following antimuscarinic medications is least likely to cross the blood-brain barrier:

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Overactive bladder (OAB) is linked to which of the following:

2. Treatment failure for OAB may be attributed to which one of the following:

3. Which of the following is TRUE regarding OAB:

4. Which of the following is a medication known to contribute to OAB:

5. Which of the following is a preferable first-line or second-line treatment choice for OAB per the American Urological Association (AUA) guidelines:

6. The medications that are used to treat OAB are

7. Mirabegron has which of the following side effects associated with its use:

8. The bladder-specific alpha-adrenergic receptor antagonists target which one of the following:

9. Which one of the following is a behavioral therapy for OAB:

10. Which of the following antimuscarinic medications is least likely to cross the blood-brain barrier:

« Return to Activity

Customers who Purchased
this Activity also Purchased